학술논문

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Document Type
Article
Source
In The Lancet 15-21 July 2017 390(10091):276-288
Subject
Primary Research
Articles
Language
ISSN
0140-6736